Skip to content

Impact of Pre-Operative Therapy Followed by Surgeon-Led Local Treatment in Patients with Advanced Gastric Cancer

Impact of Pre-Operative Therapy Followed by Surgeon-Led Local Treatment in Patients with Advanced Gastric Cancer

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500096665
Enrollment
Unknown
Registered
2025-01-27
Start date
2024-10-15
Completion date
Unknown
Last updated
2025-02-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastric Adenocarcinoma

Interventions

Unresectable gastric cancer/metastatic gastric cancer:NA
Localized resectable gastric cancer:NA

Sponsors

Zhongshan Hospital, Fudan University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1.Male or female, aged>=18 and <=80 years; 2.Pathologically confirmed gastric adenocarcinoma or adenocarcinoma of the esophagogastric junction (including only Siewert II and III types); 3.Received preoperative systemic therapy, which includes chemotherapy, immunotherapy, targeted therapy, and other treatments that conform to guideline standards and have clinical indications; 4.Underwent surgery-led local treatment: The local treatment defined in this study encompasses surgical and non-surgical approaches. Surgical treatment must involve resection of the primary tumor, with or without resection of metastatic sites. Non-surgical local treatments include: hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal implants, radiofrequency ablation (RFA) for liver or lung metastases, interventional embolization for liver metastases, radiotherapy for lung metastases, lymph node metastases, bone metastases, and other standard non-surgical local treatment strategies employed in clinical practice; 5.Signed the 'nformed Consent Form for Donation of Biological Samples and Health-Related Information' during the treatment period at Zhongshan Hospital.

Exclusion criteria

Exclusion criteria: 1.Other pathological types, such as gastric squamous cell carcinoma, neuroendocrine carcinoma, etc.; 2.Specific details of the perioperative systemic treatment regimen are unknown; 3.Missing surgical safety information within 90 days after surgery.

Design outcomes

Primary

MeasureTime frame
Event-Free Survival;Overall Survival;

Secondary

MeasureTime frame
Objective Response Rate;Disease Control Rate;Pathological Complete Response Rate;Major Pathological Response Rate;R0 Resection Rate;

Countries

China

Contacts

Public ContactZhaoqing Tang

Zhongshan Hospital, Fudan University

tang.zhaoqing@zs-hospital.sh.cn+86 138 1712 5778

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026